World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
52
Citations
9778
World Ranking
4063
National Ranking
1853

Overview

Patricia E. Fast is affiliated with the International AIDS Vaccine Initiative in the United States. Their research primarily focuses on Medicine and Immunology and Microbiology, with specific attention to Infectious Diseases, Virology, Epidemiology, Molecular Biology, and Health.

Their work concentrates on key topics such as HIV Research and Treatment, HIV/AIDS Research and Interventions, Viral Infections and Outbreaks Research, HIV/AIDS Drug Development and Treatment, SARS-CoV-2 and COVID-19 Research, Viral Infections and Vectors, and Vaccine Coverage and Hesitancy.

Frequent coauthors in Patricia E. Fast's work include Angela Huttner, Claire-Anne Siegrist, Matt A. Price, Sélidji Todagbé Agnandji, and Peter G. Kremsner. These collaborations reflect ongoing involvement in multidisciplinary research efforts within their fields of study.

Publications by Patricia E. Fast have appeared predominantly in the journal Vaccine, with six papers, followed by PLoS ONE and npj Vaccines with two papers each. Other venues include bioRxiv (Cold Spring Harbor Laboratory) and Research Square (Research Square), where two papers each have been published.

Recent selected papers authored or coauthored by Patricia E. Fast include:

  • An introduction to the Marburg virus vaccine consortium, MARVAC (2022), published in PLoS Pathogens
  • Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial (2020), published in BMJ Open
  • Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention (2022), published in The Journal of Infectious Diseases
  • Cohort Profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery (2020), published in International Journal of Epidemiology
  • Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination (2020), published in npj Vaccines

Best Publications

  • Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

    Melissa D. Simek;Wasima Rida;Frances H. Priddy;Pham Pung

  • Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

    Selidji T Agnandji;Angela Huttner;Madeleine E Zinser;Patricia Njuguna

  • Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee

    John F. Modlin;Ann M. Arvin;Patricia Fast;Martin Myers

  • Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes

    Nilu Goonetilleke;Stephen Moore;Len Dally;Nicola Winstone

  • The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

    Angela Huttner;Julie-Anne Dayer;Sabine Yerly;Christophe Combescure

  • Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV-1MN gp120, HIV-1SF2 Recombinant gp120, or Both Vaccines in Seronegative Adults

    Mary Lou Clements-Mann;Kent Weinhold;Thomas J. Matthews;Barney S. Graham

  • A human protein specific for the immunoglobulin octamer DNA motif contains a functional homeobox domain

    Hon-Sum Ko;Patricia Fast;Wesley McBride;Louis M. Staudt

  • A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

    Thomas G. Evans;Michael C. Keefer;Kent J. Weinhold;Mark Wolff

  • In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.

    Sandhya Vasan;Arlene Hurley;Arlene Hurley;Sarah J. Schlesinger;Sarah J. Schlesinger;Drew Hannaman

  • Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

    Enoch Muyanja;Aloysius Ssemaganda;Pearline Ngauv;Rafael Cubas

  • Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

    Barney S. Graham;Thomas J. Matthews;Robert B. Belshe;Mary Lou Clements

  • CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa

    Etienne Karita;Nzeera Ketter;Matt A. Price;Kayitesi Kayitenkore

  • Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

    Inese Cebere;Lucy Dorrell;Helen McShane;Alison Simmons

  • Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.

    Gaudensia Mutua;Eduard J. Sanders;Eduard J. Sanders;Peter Mwangi Mugo;Omu Anzala

  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

    Thomas G. Evans;M.Juliana McElrath;Tom Matthews;David Montefiori

  • Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.

    James C. King;John Treanor;Patricia E. Fast;Mark Wolff

  • Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity

    Barry S. Peters;Walter Jaoko;Eftyhia Vardas;George Panayotakopoulos

  • Ebola Vaccine — An Urgent International Priority

    Rupa Kanapathipillai;Ana Maria Henao Restrepo;Patricia Fast;David Wood

  • Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.

    Ira M Longini;M.Elizabeth Halloran;Azhar Nizam;Mark Wolff

  • Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

    Robert B. Belshe;Barney S. Graham;Michael C. Keefer;Geoffrey J. Gorse

Frequent Co-Authors

Matthew Price
Matthew Price University of Vermont
Jill Gilmour
Jill Gilmour Imperial College London
Josephine H. Cox
Josephine H. Cox National Institute of Allergy and Infectious Diseases
Michael C. Keefer
Michael C. Keefer University of Rochester
Eduard J. Sanders
Eduard J. Sanders University of Oxford
Pontiano Kaleebu
Pontiano Kaleebu London School of Hygiene & Tropical Medicine
Linda-Gail Bekker
Linda-Gail Bekker University of Cape Town
Walter Jaoko
Walter Jaoko University of Nairobi
Barney S. Graham
Barney S. Graham Morehouse School of Medicine
Susan Allen
Susan Allen Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, expanding into related healthcare fields such as Nursing can open diverse career opportunities. Many professionals pursue specialized tracks through programs like the cheapest pmhnp programs, which provide cost-effective ways to advance in psychiatric mental health nursing.

Nurse Practitioners (NPs), including those with a Doctor of Nursing Practice (DNP) degree, often explore career growth by transitioning into acute care roles. Resources on how to smoothly make this shift, such as guides on fnp to acute care certification, are valuable for expanding clinical skills.

Understanding compensation is also crucial. The how much do dnps make analysis highlights salary variations by location, helping graduates assess their earning potential across states.

For those looking to accelerate their education, enrolling in one of the accelerated np program options can fast-track licensure and clinical readiness while balancing other commitments.

Integrating Immunology knowledge with nursing specialties or advanced practice pathways offers a dynamic career trajectory with multiple options for continual learning and professional success.

Best Scientists Citing Patricia E. Fast

Trending Scientists